Mozaffarul Islam1, Jharna Datta2, James C Lang3, Theodoros N Teknos3. 1. Department of Otolaryngology-Head and Neck Surgery, The Ohio State University, Wexner Medical Center, Columbus, OH, USA; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Wexner Medical Center, Columbus, OH, USA. Electronic address: Mozaffarul.Islam@osumc.edu. 2. Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Wexner Medical Center, Columbus, OH, USA. 3. Department of Otolaryngology-Head and Neck Surgery, The Ohio State University, Wexner Medical Center, Columbus, OH, USA; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.
Abstract
OBJECTIVE: RhoC a pro-metastatic oncogene is constitutively active in many head and neck squamous cell carcinomas. MicroRNA-138 which possesses a documented tumor suppressor function can bind to the 3'UTR of RhoC mRNA and inhibit its activity. We hypothesize that miR-138 can inhibit the function of RhoC and consequently the activation of downstream target molecules involve in the signaling cascade. For this reason we investigated the role of miR-138 in HNSCC. METHODS: In vitro studies were carried out to evaluate the role of miR-138 in HNSCC cell lines and in primary tumors obtained from HNSCC patients. Real time RT-PCR, Western blot, cell motility, invasion and colony formation assays were performed according to standard procedures. RESULTS: Data obtained by G-LISA and real time PCR shows an inverse correlation between RhoC expression and miR-138 in HNSCC cell lines. Additionally, we obtained a similar pattern of RhoC and miR-138 expression in primary tumors from HNSCC patients. Over expression of miR-138 in HNSCC lines showed down regulation of RhoC, as well as a decrease in cell motility, invasion colony and stress fiber formation. Furthermore, a significant down regulation was observed for FAK, Src and Erk(1/2) upon miR-138 overexpression. CONCLUSION: These findings strongly suggest that the inhibition of RhoC can be achieved by over expressing miR-138, which further attenuates the downstream signaling cascade leading to cancer progression and survival. Moreover, this study for the first time shows that down regulation of FAK, Src and Erk(1/2) by miR-138 overexpression is due to inhibition of RhoC in HNSCC. Published by Elsevier Ltd.
OBJECTIVE:RhoC a pro-metastatic oncogene is constitutively active in many head and neck squamous cell carcinomas. MicroRNA-138 which possesses a documented tumor suppressor function can bind to the 3'UTR of RhoC mRNA and inhibit its activity. We hypothesize that miR-138 can inhibit the function of RhoC and consequently the activation of downstream target molecules involve in the signaling cascade. For this reason we investigated the role of miR-138 in HNSCC. METHODS: In vitro studies were carried out to evaluate the role of miR-138 in HNSCC cell lines and in primary tumors obtained from HNSCC patients. Real time RT-PCR, Western blot, cell motility, invasion and colony formation assays were performed according to standard procedures. RESULTS: Data obtained by G-LISA and real time PCR shows an inverse correlation between RhoC expression and miR-138 in HNSCC cell lines. Additionally, we obtained a similar pattern of RhoC and miR-138 expression in primary tumors from HNSCC patients. Over expression of miR-138 in HNSCC lines showed down regulation of RhoC, as well as a decrease in cell motility, invasion colony and stress fiber formation. Furthermore, a significant down regulation was observed for FAK, Src and Erk(1/2) upon miR-138 overexpression. CONCLUSION: These findings strongly suggest that the inhibition of RhoC can be achieved by over expressing miR-138, which further attenuates the downstream signaling cascade leading to cancer progression and survival. Moreover, this study for the first time shows that down regulation of FAK, Src and Erk(1/2) by miR-138 overexpression is due to inhibition of RhoC in HNSCC. Published by Elsevier Ltd.
Entities:
Keywords:
Erk(1/2); FAK; Head and neck cancer; RhoC; Src; miR-138
Authors: Jharna Datta; Huban Kutay; Mohd W Nasser; Gerard J Nuovo; Bo Wang; Sarmila Majumder; Chang-Gong Liu; Stefano Volinia; Carlo M Croce; Thomas D Schmittgen; Kalpana Ghoshal; Samson T Jacob Journal: Cancer Res Date: 2008-07-01 Impact factor: 12.701
Authors: Steven S Chang; Wei Wen Jiang; Ian Smith; Luana M Poeta; Shahnaz Begum; Chad Glazer; Shannon Shan; William Westra; David Sidransky; Joseph A Califano Journal: Int J Cancer Date: 2008-12-15 Impact factor: 7.396
Authors: Christian Cordes; Ann-Kristin Münzel; Pierre Rudolph; Markus Hoffmann; Ivo Leuschner; Stefan Gottschlich Journal: Anticancer Res Date: 2009-04 Impact factor: 2.480
Authors: Sohail F Tavazoie; Claudio Alarcón; Thordur Oskarsson; David Padua; Qiongqing Wang; Paula D Bos; William L Gerald; Joan Massagué Journal: Nature Date: 2008-01-10 Impact factor: 49.962
Authors: Gabriele Siegel; Gregor Obernosterer; Roberto Fiore; Martin Oehmen; Silvia Bicker; Mette Christensen; Sharof Khudayberdiev; Philipp F Leuschner; Clara J L Busch; Christina Kane; Katja Hübel; Frank Dekker; Christian Hedberg; Balamurugan Rengarajan; Carsten Drepper; Herbert Waldmann; Sakari Kauppinen; Michael E Greenberg; Andreas Draguhn; Marc Rehmsmeier; Javier Martinez; Gerhard M Schratt Journal: Nat Cell Biol Date: 2009-05-24 Impact factor: 28.824
Authors: Sarah U Morton; Paul J Scherz; Kimberly R Cordes; Kathryn N Ivey; Didier Y R Stainier; Deepak Srivastava Journal: Proc Natl Acad Sci U S A Date: 2008-11-12 Impact factor: 11.205
Authors: Jun Wei; Edjah K Nduom; Ling-Yuan Kong; Yuuri Hashimoto; Shuo Xu; Konrad Gabrusiewicz; Xiaoyang Ling; Neal Huang; Wei Qiao; Shouhao Zhou; Cristina Ivan; Greg N Fuller; Mark R Gilbert; Willem Overwijk; George A Calin; Amy B Heimberger Journal: Neuro Oncol Date: 2015-12-11 Impact factor: 12.300